“What if aging didn’t have to suck?”

Anti-aging startup gets funding even with controversial therapy

#Health

Fri, Sep 7th, 2018 09:00 by capnasty NEWS

According to MIT Technology Review, San Francisco-based startup Elevian, which is looking on whether daily injections of a protein called GDF11 can rejuvenate the body, has raised $5.5 million in seed funding, despite controversy behind the science involved.

Wagers’s discoveries drew wide interest, but when large drug companies tried to replicate the research, they couldn’t. In a 2015 study, for example, scientists at Novartis found that GDF11 levels do not fall with age and that the protein actually inhibits rather than promotes muscle regeneration.

  256

 

You may also be interested in:

US Centres for Disease Control Are Zombie Ready
“Scientists successfully transplanted bioengineered lungs into pigs for the first time.”
“The synergy between biotechnology and artificial intelligence is going to revolutionize everything around us.”
Gene Therapy to Restore Sight to Near Blind Patients
“We simply called it ageing.”